全甲状腺切除与甲状腺腺叶切除在成人局限性甲状腺髓样癌中的生存比较:倾向匹配分析
本研究基于SEER数据库(2000-2018)及中国三中心回顾性队列,比较全甲状腺切除与腺叶切除对局限性甲状腺髓样癌生存的影响。倾向匹配后各122例,中位随访99个月,两组10年总生存率分别为85.2%和83.1%,疾病特异性生存率分别为100%和96.8%,差异均无统计学意义。结论提示早期局限性甲状腺髓样癌中腺叶切除可能已足够。
要点
- 局限性甲状腺髓样癌中,全甲状腺切除与腺叶切除的生存无显著差异。
- 倾向匹配后10年总生存率分别为85.2%与83.1%,疾病特异性生存率100%与96.8%。
- 早期局限性甲状腺髓样癌中,甲状腺腺叶切除可能是足够的术式选择。
核心结论
- 本研究提示,对于早期局限性甲状腺髓样癌患者,甲状腺切除范围不影响生存,腺叶切除可能已足够。
研究设计与样本
- 基于SEER数据库(2000-2018)识别局限性甲状腺髓样癌患者,并经倾向评分匹配后各122例行全甲状腺切除或腺叶切除,中位随访99个月。
- 另回顾性纳入中国三个医疗中心2010-2020年47例局限性甲状腺髓样癌患者(全甲状腺切除29例,腺叶切除18例),中位随访47个月。
主要发现
- 倾向匹配后全甲状腺切除组与腺叶切除组10年总生存率分别为85.2%(77.9%-90.7%)和83.1%(75.5%-90.7%)。
- 10年疾病特异性生存率在全甲状腺切除组为100%,在腺叶切除组为96.8%(93.1%-100%)。
- 总生存的风险比(HR)为0.83(95%CI 0.44-1.57,P=.57),疾病特异性生存的HR为0.49(95%CI 0.10-2.41,P=.39),均无统计学显著差异。
- 中国独立队列中,两组在中位随访47个月内均未观察到死亡。
临床怎么用
- 对于早期局限性甲状腺髓样癌,甲状腺腺叶切除可作为全甲状腺切除的替代选择,但需结合术前评估和个体情况决策。
局限性
- SEER数据库为回顾性分析,可能存在选择偏倚和未测量混杂因素。
- 中国独立队列样本量较小(47例),随访时间较短(中位47个月),且未观察到死亡事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to clarify whether the extent of thyroidectomy (total thyroidectomy vs thyroid lobectomy) influences survival in adults with localized medullary thyroid cancer. METHODS: Patients with localized medullary thyroid cancer were identified using the Surveillance, Epidemiology, and End Results database (2000-2018). An independent cohort of patients with localized medullary thyroid cancer were retrospectively reviewed from three medical centers in China from 2010 to 2020. The patients were grouped by the extent of surgery (total thyroidectomy vs thyroid lobectomy). Primary end points were overall survival and disease-specific survival. RESULTS: From 1,686 patients with medullary thyroid cancer identified in SEER, 1,122 patients met inclusion for matching, with a median follow-up of 99 months. After propensity score matching, 122 patients underwent a total thyroidectomy and 122 patients underwent a thyroid lobectomy. The 10-year overall survival was 85.2% (77.9%-90.7%) and 83.1% (75.5%-90.7%) in total thyroidectomy group and in thyroid lobectomy group, respectively. The 10-year disease-specific survival was 100% and 96.8% (93.1%-100%) in total thyroidectomy group and in thyroid lobectomy group, respectively. There was no statistically significant difference in overall survival or disease-specific survival in patients with localized medullary thyroid cancer undergoing total thyroidectomy or thyroid lobectomy (hazard ratio = 0.83, 95% confidence interval 0.44-1.57, P = .57 and hazard ratio = 0.49, 95% confidence interval 0.10-2.41, P = .39, respectively). Forty-seven patients with localized medullary thyroid cancer were identified in an independent Chinese cohort (n = 29 in total thyroidectomy group vs n = 18 in thyroid lobectomy group). After a median follow-up of 47 months, there was no mortality observed in either group. CONCLUSION: This study suggests that the extent of thyroidectomy does not influence survival for patients with early-stage localized medullary thyroid cancer and that thyroid lobectomy might be adequate in this patient population.
引用
- Liang W, Shi J, Zhang H, et al. Total thyroidectomy vs thyroid lobectomy for localized medullary thyroid cancer in adults: A propensity-matched survival analysis. Surgery. 2022. PMID: 35995619. doi:10.1016/j.surg.2022.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。